GlassScriptPhysician profile
Nancy Hindalong
NPI 1164075560
$7,108.77
in general payments reported to CMS, 2019-2025
31 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $631 · 2022: $1,244 · 2023: $1,886 · 2024: $1,925 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,873 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,873.21 |
| Education | $359.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,159.02 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $981.42 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $781.77 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $634.04 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $604.39 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $558.54 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $415.36 | 2021-2025 | |
| Lilly USA, LLC | $386.27 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $357.42 | 2021-2025 | |
| Leo Pharma INC. | $246.35 | 2021-2025 | Adbry |
| Pfizer INC. | $156.21 | 2022-2025 | |
| Amgen INC. | $146.38 | 2022-2025 | Otezla, Otezla |
| Kerecis Limited | $134.12 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Hill Dermaceuticals, INC. | $79.98 | 2025 | Tolak |
| Janssen Scientific Affairs, LLC | $73.02 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $48.27 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $39.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.78 | 2022-2023 | Spevigo |
| Dermavant Sciences, INC. | $35.24 | 2023 | Vtama |
| Mallinckrodt Hospital Products INC. | $33.53 | 2025 | Acthar |
| Arcutis Biotherapeutics, INC. | $24.70 | 2023 | |
| Allergan, INC. | $24.04 | 2022 | |
| Strata Skin Sciences, INC. | $22.93 | 2025 | Xtrac |
| Biofrontera INC. | $21.91 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Organon LLC | $21.67 | 2025 | Vtama |
| Glaxosmithkline, LLC. | $17.77 | 2023 | Shingrix |
| Vyne Pharmaceuticals INC. | $16.78 | 2021 | |
| Incyte Corporation | $15.21 | 2022 | |
| Galderma Laboratories, L.P. | $13.64 | 2025 | Nemluvio |
| Dermira, INC. | $11.82 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Hindalong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.